

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Lee et al.**

Application Serial No.: **Not Yet Known**

Group Art Unit: **Not Yet Known**

Filed: **Filed concurrently herewith**

Examiner: **Not Yet Known**

For: ***Water-Soluble Etoposide Analogs and Methods of Use Thereof***

Date: November 13, 2003

MAIL STOP PATENT APPLICATION

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP. No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,



Kenneth D. Sibley
Registration No. 31,665

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number: EY318417651 US
Date of Deposit: November 13, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Lyndsey D. Hall, CP
Certified Paralegal

Substitute form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known				
				Application Number		To Be Assigned		
				Filing Date		Concurrently Herewith		
				First Named Inventor		Kuo-Hsiung Lee		
				Group Art Unit		Unknown		
Examiner Name		Unknown						
Sheet	1	of	1	Attorney Docket Number		5470.397		
U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number	Kind Code (if known)					
	1	4,958,010		Kadow et al.	9/18/90			
	2	5,132,322		Lee et al.	7/21/92			
	3	5,332,811		Lee et al.	7/26/94			
	4	5,300,500		Lee et al.	4/5/94			
	5	5,338,867		Choy et al.	8/16/94			
	6	5,541,223		Lee et al.	7/30/96			
	7	5,571,914		Terada et al.	11/5/96			
	8	6,281,198		Monneret et al.	8/28/01			
FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						T
	9	XIAO ET AL., <i>Antitumor Agents. 229. Design, Synthesis, and Biological Evaluation of Novel 4β-[4"-Benzamido)-Amino]-4'0'Demethyl-Epipodophyllotoxins and Related Derivatives, Unpublished draft paper.</i>						

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.